Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer treatment.
• On-target/off-tumor toxicity remains a significant challenge, limiting its clinical application.
• This toxicity occurs when CAR T-cells attack healthy tissues expressing the target antigen.

Purpose of the Study:

• To develop a novel strategy to prevent on-target/off-tumor toxicity in CAR T-cell therapy.
• To engineer CAR T-cells with a safety switch responsive to the tumor microenvironment.
• To investigate the potential of oxygen-regulated CAR expression for targeted cancer treatment.

Main Methods:

• Designed a CAR construct with an oxygen-sensitive regulatory element.
• Introduced the engineered CAR into T-cells.
• Evaluated CAR T-cell activity and specificity in preclinical models.
• Assessed the impact of oxygen levels on CAR expression and function.

Main Results:

• The engineered CAR's expression was successfully controlled by oxygen levels.
• CAR T-cell activity was selectively inhibited in low-oxygen tumor environments.
• On-target/off-tumor toxicity was significantly reduced or prevented in relevant models.
• Demonstrated the feasibility of using the tumor microenvironment as a safety mechanism.

Conclusions:

• Oxygen-regulated CAR design offers a promising approach to mitigate CAR T-cell toxicity.
• This strategy enhances the safety profile of CAR T-cell therapy.
• Further development could lead to safer and more effective cancer immunotherapies.